Uncommon Cents Investing LLC Has $748,000 Holdings in Fresenius Medical Care AG (NYSE:FMS)

Uncommon Cents Investing LLC increased its position in shares of Fresenius Medical Care AG (NYSE:FMS) by 19.7% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 35,920 shares of the company’s stock after buying an additional 5,900 shares during the period. Uncommon Cents Investing LLC’s holdings in Fresenius Medical Care were worth $748,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of the company. Arrowstreet Capital Limited Partnership increased its stake in Fresenius Medical Care by 77.1% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 1,570,817 shares of the company’s stock valued at $25,667,000 after purchasing an additional 683,851 shares in the last quarter. Morgan Stanley increased its stake in Fresenius Medical Care by 3.7% in the third quarter. Morgan Stanley now owns 1,041,447 shares of the company’s stock valued at $22,433,000 after purchasing an additional 36,820 shares in the last quarter. Balyasny Asset Management L.P. grew its holdings in shares of Fresenius Medical Care by 69.5% during the first quarter. Balyasny Asset Management L.P. now owns 750,610 shares of the company’s stock valued at $15,958,000 after buying an additional 307,801 shares during the last quarter. Goldman Sachs Group Inc. grew its holdings in shares of Fresenius Medical Care by 58.8% during the second quarter. Goldman Sachs Group Inc. now owns 736,847 shares of the company’s stock valued at $17,633,000 after buying an additional 272,886 shares during the last quarter. Finally, Millennium Management LLC acquired a new position in shares of Fresenius Medical Care during the second quarter valued at about $16,738,000. Institutional investors own 8.25% of the company’s stock.

Fresenius Medical Care Stock Performance

FMS traded down $0.07 during midday trading on Thursday, reaching $19.29. The company had a trading volume of 204,409 shares, compared to its average volume of 455,035. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.07 and a current ratio of 1.42. The stock has a market cap of $11.32 billion, a PE ratio of 20.96, a P/E/G ratio of 0.91 and a beta of 1.00. Fresenius Medical Care AG has a 12-month low of $16.37 and a 12-month high of $27.72. The business has a 50-day moving average price of $19.75 and a two-hundred day moving average price of $19.82.

Fresenius Medical Care (NYSE:FMS) last released its earnings results on Tuesday, February 20th. The company reported $0.47 earnings per share for the quarter, beating analysts’ consensus estimates of $0.36 by $0.11. The firm had revenue of $5.37 billion for the quarter, compared to analysts’ expectations of $5.32 billion. Fresenius Medical Care had a net margin of 2.56% and a return on equity of 4.99%. On average, sell-side analysts expect that Fresenius Medical Care AG will post 1.53 earnings per share for the current fiscal year.

Analyst Ratings Changes

FMS has been the subject of a number of analyst reports. Morgan Stanley cut shares of Fresenius Medical Care from an “equal weight” rating to an “underweight” rating in a report on Monday, January 8th. StockNews.com upgraded shares of Fresenius Medical Care from a “hold” rating to a “strong-buy” rating in a report on Wednesday, February 21st. One investment analyst has rated the stock with a sell rating, five have issued a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $32.25.

Fresenius Medical Care Company Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.